Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Demecarium
2. Demecastigmine
3. Humorsol
4. Tosmilen
1. 56-94-0
2. Humorsol
3. Demekastigmine Bromide
4. Demecarii Bromidum
5. Bromuro De Demecario
6. Bromure De Demecarium
7. Bc-48
8. N,n'-bis(3-trimethylammoniumphenoxycarbonyl)-n,n'-dimethyldecamethylenediamine Dibromide
9. 3,3'-(((decane-1,10-diylbis(methylazanediyl))bis(carbonyl))bis(oxy))bis(n,n,n-trimethylbenzenaminium) Bromide
10. 56-94-0 (bromide)
11. 61d5v4oktp
12. (m-hydroxyphenyl)trimethylammonium Bromide Decamethylenebis(methylcarbamate)
13. (m-hydroxyphenyl)trimethylammonium Bromide Decamethylenebis(methylcarbamate) (2:1)
14. Decamethylenebis(n-methylcarbamic Acid M-dimethylaminophenyl Ester) Bromomethylate
15. Chebi:4391
16. Frumtosnil
17. Visumiotic
18. Tonilen
19. Tosmicil
20. Tosmilen
21. Tosmilene
22. Visumatic
23. Demekarium Bromide
24. Benzenaminium, 3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(n,n,n-trimethyl-, Dibromide
25. Trimethyl-[3-[methyl-[10-[methyl-[3-(trimethylazaniumyl)phenoxy]carbonylamino]decyl]carbamoyl]oxyphenyl]azanium;dibromide
26. Demecarii Bromidum [inn-latin]
27. Bc 48
28. Bromure De Demecarium [inn-french]
29. Bromuro De Demecario [inn-spanish]
30. Humorsol (tn)
31. 3,3'-(((decane-1,10-diylbis(methylazanediyl))bis(carbonyl))bis(oxy))bis(n,n,n-trimethylbenzenaminium) Bromide.
32. Hsdb 2168
33. Einecs 200-301-9
34. Unii-61d5v4oktp
35. Demecarium Bromide (usp/inn)
36. Decamethylenebis(m-dimethylaminophenyl-n-methylcarbamate) Dimethobromide
37. Demecarium Bromide [usp:inn:ban]
38. Ammonium, (m-hydroxyphenyl)trimethyl-, Bromide, Decamethylenebis(methylcarbamate) (2:1)
39. Ammonium, (m-hydroxyphenyl)trimethyl-, Bromide, Decamethylenebis(methylcarbamate)
40. Schembl34283
41. Demecarium Bromide [mi]
42. Chembl1200514
43. Demecarium Bromide [inn]
44. Hy-b1626a
45. Demecarium Bromide [hsdb]
46. Demecarium Bromide [vandf]
47. Hms2096l14
48. Hms3713l14
49. Hms3887m05
50. Demecarium Bromide [mart.]
51. Bcp24065
52. Demecarium Bromide [usp-rs]
53. Demecarium Bromide [who-dd]
54. Ac-305
55. Decamethylenebis(m-dimethylaminophenyl-n-methylcarbamate)dimethobromide
56. Akos015896671
57. Ccg-220616
58. 3,3'-{decane-1,10-diylbis[(methylcarbamoyl)oxy]}bis(n,n,n-trimethylanilinium) Dibromide
59. Demecarium Bromide [orange Book]
60. As-11735
61. Demecarium Bromide [usp Monograph]
62. Cs-0030928
63. Ft-0698614
64. D00667
65. A924356
66. Sr-01000838877
67. Q5255128
68. Sr-01000838877-2
69. W-105496
70. 3,3'-(((decane-1,10-diylbis(methylazanediyl))bis(carbonyl))bis(oxy))bis(n,n,n-trimethylbenzenaminium)bromide
71. 3,3'-(1,10-decanediylbis((methylimino)carbonyloxy))bis(n,n,n-trimethylbenzenaminium)dibromide
72. 3,3'-(decane-1,10-diylbis(methylazanediyl))bis(oxomethylene)bis(oxy)bis(n,n,n-trimethylbenzenaminium) Bromide
| Molecular Weight | 716.6 g/mol |
|---|---|
| Molecular Formula | C32H52Br2N4O4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 17 |
| Exact Mass | 716.23348 g/mol |
| Monoisotopic Mass | 714.23553 g/mol |
| Topological Polar Surface Area | 59.1 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 686 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Cholinesterase Inhibitors; Miotics
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
/IN TREATMENT OF ESOTROPIA/ THERAPY SHOULD BE DISCONTINUED AFTER 4 MO IF INSTILLATION AS OFTEN AS EVERY 2 DAYS IS STILL REQUIRED.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
/CONGESTIVE IRITIS, IRIDOCYCLITIS, & CONJUNCTIVAL & INTRAOCULAR HYPEREMIA/ ... CAN BE MINIMIZED BY INSTILLATION OF SOLN OF LOWEST EFFECTIVE CONCN @ BEDTIME, & THEY OFTEN SUBSIDE AFTER FIRST FEW DAYS OF THERAPY. INSTILLATION OF 10% PHENYLEPHRINE HYDROCHLORIDE SOLN MAY BE HELPFUL IF CIRCUMCORNEAL INJECTION IS SEVERE.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
FOLLOWING INSTILLATION OF DEMECARIUM IN EYE, MIOSIS APPEARS WITHIN 1 HR & REACHES ITS MAX IN 2 TO 4 HR. REDUCTION OF INTRAOCULAR PRESSURE OCCURS IN CA 12 HR & IS FREQUENTLY PRECEDED BY SLIGHT RISE IN PRESSURE. PUPILLARY CONSTRICTION & DECR INTRAOCULAR PRESSURE MAY PERSIST FOR WK OR MORE FOLLOWING SINGLE INSTILLATION.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
For more Therapeutic Uses (Complete) data for DEMECARIUM BROMIDE (10 total), please visit the HSDB record page.
GONIOSCOPIC EXAM SHOULD CONFIRM THAT ANGLE OF EYE IS OPEN PRIOR TO DEMECARIUM THERAPY... IN PT WITH NARROW ANGLE (CONGESTIVE) GLAUCOMA, INTRAOCULAR PRESSURE MAY BE INCR & ACUTE ATTACKS MAY BE PPT. ...INCR IN INTRAOCULAR PRESSURE MAY OCCUR EVEN WHEN ANGLE IS OPEN...
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
DEMECARIUM IS CONTRAINDICATED IN PT WITH MARKED VASOMOTOR INSTABILITY, BRONCHIAL ASTHMA, SPASTIC GI CONDITIONS, PEPTIC ULCER, SEVERE BRADYCARDIA OR HYPOTENSION, RECENT MYOCARDIAL INFARCTION, EPILEPSY, OR PARKINSONISM.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
.../DEMECARIUM/ SHOULD BE USED WITH GREAT CAUTION, IF AT ALL, IN PT WITH HISTORY OF RETINAL DETACHMENT & IN THOSE WITH OCULAR HYPERTENSION ACCOMPANIED BY INTRAOCULAR INFLAMMATORY PROCESSES. ...CONTRAINDICATED IN PT WITH NARROW ANGLE GLAUCOMA.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
/DEMECARIUM/...SHOULD NOT BE ADMIN PRIOR TO IRIDECTOMY IN ANGLE-CLOSURE GLAUCOMA BECAUSE...MORE APT TO AGGRAVATE ANGLE CLOSURE THAN WEAKER MIOTICS.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 922
Cholinesterase Inhibitors
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)
DEMECARIUM IS ABSORBED THROUGH CONJUNCTIVAL SAC AS WELL AS THROUGH INTACT SKIN... /DEMECARIUM/
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
/INCR FACILITY OF AQ OUTFLOW/...ACCOMPANIED BY VASODILATATION OF CONJUNCTIVAL VESSELS & INCR PERMEABILITY OF BLOOD-AQ BARRIER. INDIRECT DECR IN ACTIVITY OF EXTRAOCULAR MUSCLES OF CONVERGENCE ALSO OCCURS. ...CHOLINESTERASE INHIBITION PRODUCED BY DEMECARIUM IS "REVERSIBLE".
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
DEMECARIUM BROMIDE...IS A QUATERNARY AMMONIUM ANTICHOLINESTERASE DRUG. ... RESULTING ACCUM OF ACETYLCHOLINE PRODUCES MIOSIS & STIMULATES CILIARY MUSCLE...REDUCING INTRAOCULAR PRESSURE BY INCR FACILITY OF AQ OUTFLOW.
American Hospital Formulary Service. Volumes I and II. Washington, DC: American Society of Hospital Pharmacists, to 1984., p. 52:20
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A DEMECARIUM BROMIDE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DEMECARIUM BROMIDE, including repackagers and relabelers. The FDA regulates DEMECARIUM BROMIDE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DEMECARIUM BROMIDE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of DEMECARIUM BROMIDE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A DEMECARIUM BROMIDE supplier is an individual or a company that provides DEMECARIUM BROMIDE active pharmaceutical ingredient (API) or DEMECARIUM BROMIDE finished formulations upon request. The DEMECARIUM BROMIDE suppliers may include DEMECARIUM BROMIDE API manufacturers, exporters, distributors and traders.
click here to find a list of DEMECARIUM BROMIDE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing DEMECARIUM BROMIDE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for DEMECARIUM BROMIDE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture DEMECARIUM BROMIDE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain DEMECARIUM BROMIDE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a DEMECARIUM BROMIDE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of DEMECARIUM BROMIDE suppliers with NDC on PharmaCompass.
DEMECARIUM BROMIDE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DEMECARIUM BROMIDE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DEMECARIUM BROMIDE GMP manufacturer or DEMECARIUM BROMIDE GMP API supplier for your needs.
A DEMECARIUM BROMIDE CoA (Certificate of Analysis) is a formal document that attests to DEMECARIUM BROMIDE's compliance with DEMECARIUM BROMIDE specifications and serves as a tool for batch-level quality control.
DEMECARIUM BROMIDE CoA mostly includes findings from lab analyses of a specific batch. For each DEMECARIUM BROMIDE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DEMECARIUM BROMIDE may be tested according to a variety of international standards, such as European Pharmacopoeia (DEMECARIUM BROMIDE EP), DEMECARIUM BROMIDE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DEMECARIUM BROMIDE USP).
LOOKING FOR A SUPPLIER?
